Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person10
EyePoint, Inc.
Company
AvePoint, Inc.
Company
SailPoint, Inc.
Company
Eagle Point Income Co Inc.
Company
CENTERPOINT ENERGY INC
Company
ESG Inc.
Company
ChargePoint Holdings, Inc.
Company
NexPoint Capital, Inc.
Company
ClearPoint Neuro, Inc.
Company
EXPONENT INC
Company
Primary record12
EyePoint, Inc. filed SCHEDULE 13G/A
0001623632-26-001650.txt : 20261104 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001056288 XXXXXXXX LIVE 3 COMMON STOCK 10/31/2026 0001314102 EYEPOINT, INC. 30233G209 480 Pleasant Street Suite C400 Watertown MA
EyePoint, Inc. filed SCHEDULE 13G/A
0002100119-26-001594.txt : 20261030 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0002100119 XXXXXXXX LIVE 1 Common Stock 09/30/2026 0001314102 EyePoint Inc 30233G209 480 Pleasant Street Suite C-400 Watertown MA
EyePoint, Inc. filed SCHEDULE 13G
on August 5, 2026. KEVIN TANG X1 0.00 8250200.00 0.00 8250200.00 8250200.00 N 9.6 IN Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI, TCP III, TCP IV and TCM. TANG CAPITAL PARTNERS, LP DE 0
EyePoint, Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On October 19, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing, among other things, its estimated cash, cash equivalents and short-term inve
EyePoint, Inc. filed 8-K
Item 8.01 Other Events. On October 19, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing topline data for LUCIA, one of its pivotal Phase 3 clinical trials evaluating DURAVYU for wet age-related macu
EyePoint, Inc. filed SCHEDULE 13G/A
0001623632-26-001550.txt : 20261007 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001056288 XXXXXXXX LIVE 2 COMMON STOCK 09/30/2026 0001314102 EyePoint 30233G209 480 Pleasant Street, Suite C400 Watertown MA 0247
EyePoint, Inc. filed 8-K
Item 8.01 Other Events. On September 10, 2026, EyePoint, Inc. posted an updated investor presentation on its website at www.eyepoint.bio. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated b
EyePoint, Inc. filed SCHEDULE 13G
0001274173-26-000222.txt : 20260908 SCHEDULE 13G 1 primary_doc.xml X0202 SCHEDULE 13G 0001274173 XXXXXXXX LIVE Common Stock 08/31/2026 0001314102 EYEPOINT, INC. 30233G209 480 PLEASANT STREET SUITE C400 WATERTOWN MA 02472
EyePoint, Inc. filed 4
SEC form 4 filed by EyePoint, Inc. (CIK 1314102) on 2026-08-24.
EyePoint, Inc. filed 4
SEC form 4 filed by EyePoint, Inc. (CIK 1314102) on 2026-08-18.
EyePoint, Inc. filed 8-K
Item 8.01 Other Events. On August 17, 2026, EyePoint, Inc. (the Company ) issued a press release announcing topline data for LUGANO, one of its pivotal Phase 3 clinical trials evaluating DURAVYU for wet age-related macul
EyePoint, Inc. filed SCHEDULE 13G/A
on May 7, 2026, that there were 83,841,298 shares of Common Stock of the Issuer outstanding as of May 1, 2026. Y N See Item 2. The Cormorant Funds have the right to receive or the power to direct the receipt of dividends